Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    674

Stocks News & Analysis

stocks

Production increase on track for ASX hydrocarbon producer

Our view after lower earnings.
stocks

Market pricing in further upside in overvalued ASX bank

We view the shares are materially overvalued.
stocks

Chart of the Week: Lithium is rebounding on rising demand

The mining sector is significantly overvalued on average but select value to be found.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,238.7021.500.23%
CAC 408,429.030.000.00%
DAX 4025,278.21279.811.12%
Dow JONES (US)49,549.6416.450.03%
FTSE 10010,686.18130.011.23%
HKSE26,705.94138.820.52%
NASDAQ22,677.9999.610.44%
Nikkei 22557,143.84577.351.02%
NZX 50 Index13,247.02129.110.98%
S&P 5006,860.7717.550.26%
S&P/ASX 2009,007.0012.800.14%
SSE Composite Index4,082.0751.95-1.26%

Market Movers